
Most people know that we are herbalists and naturopaths.
The vast majority of our work is with plants, and even personally, we avoid pharmaceutical
drugs wherever possible, because it is our experience that nature usually provides the best solution --
without the smorgasbord of side effects.

One condition we encounter frequently in our work is
fungal and yeast overgrowth. Candidiasis, by itself, is a big problem. For many,
Lugol's Iodine is a traditional choice. It is naturally occurring,
of course, and many people are deficient in iodine anyway. (The same can be
said for
oregano oil and
cinnamon oil,
both traditionally used essential oils.)

For this reason, we were interested in a compound that
has been widely discussed among candida sufferers, despite the fact that it is most
decidedly not natural. We've known about lufenuron and it effects since at least 2014,
when we had the opportunity to speak with Sarah Vaughter, another vendor of the product. Later,
we had the chance to talk extensively with another vendor who has since retired from the business.
Our concerns centered around safety and efficacy, as they do in examining any new product.

After weeks of study, we came to the conclusion that the
naysayers of "the lufenuron approach" are largely vendors with their own candida program and/or book,
who are simply attempting to kick a competitor to the curb. Most of their arguments are disingenuous.

We do not recommend that you take this product on the mere
suspicion that you
might have fungus. It's better if you can get properly tested.
U.S. Patent Number 6,110,971: Original Novartis patent for Lufenuron, entitled,
"Fungicide Composition Comprising A Benzoylphenylurea" -- The purpose and range of function of Lufenuron is revealed in
the patent itself: "The invention allows a therapeutic treatment of a variety of fungal infections. These may include systemic infections
as well as topical fungal infections. In particular, and by a preferred embodiment, the present invention allows treatment of skin fungal
infections in both humans and animals, nail or genital fungal infections in humans, eye fungal infections or ear fungal infections in both
humans and animals, and others. Particular examples of fungal infections which may be treated in accordance with the invention are caused by
dermatophytes such as those of the genus Microsporum (e.g. Microsporum Canis) which cause various skin fungal infections of the skin, nails or hair;
those of the genus Aspergillas, and yeasts, e.g. Malassezia or Candida."
Use of lufenuron for treating fungal infections of dogs and cats: 297 cases (1997-1999) --
Conclusions and clinical relevance: Results of this study suggest that lufenuron provides an effective, convenient,
and rapid method for treating fungal infections in dogs and cats.
Control of cutaneous mycosis in five chimpanzees (Pan troglodytes) with lufenuron -- Five chimpanzees at the Limbe
Wildlife Centre in Cameroon, of both sexes and between six and eight years of age, were treated with lufenuron at a dose rate of 60 mg/kg
bodyweight to control various types of mycotic skin infections. The 409.8 mg tablets were administered by mixing them with milk and avocado.
Each animal received two or three treatments three weeks apart. Most of them improved significantly during the two to three weeks after the
first treatment, and they had completely recovered two to four months later. All the chimpanzees accepted the medication readily, and no adverse
drug reactions were observed either immediately after the treatment or during the subsequent eight to 10 months.
In vitro efficacy of lufenuron against filamentous fungi and blood concentrations after PO administration in horses --
The value of this study concerns toxicity. True efficacy has to be measured "in vivo," in other words, how does the compound perform
in the organism being studied. This study doesn't measure that. What's important here is that "Lufenuron was detected in the blood of all
but one (out of 21) horse and showed no adverse effects."
Lufenuron: A Potential Chitin Synthesis Inhibitor Against Aedes aegypti L. --
This is a study of the effects of lufenuron against
Aedes aegypti, a mosquito and dengue vector. It's importance is that it advances
the understanding of how Lufenuron, an IGR, Insect Growth Regulator, works against invertebrate chitin.
Dr. Myhill (UK): Lufenuron -- a potentially useful treatment to treat candida --
One practitioner's perspective.
Marty Ross, M.D.: Lufenuron: An Experimental Yeast Treatment -- One physician's comments, noting that there are no human safety studies.
Lufenuron -- Candida Treatment -- Danielle M. Bryant is an author and therapist, who has struggled with
severe candidiasis. On this page she gives a "blow-by-blow" of her experiences with lufenuron. She doesn't think lufenuron is a
panacea (neither do we).
Lufenuron Candida Treatment Patient Guide -- This is the 14-page PDF treatment guide produced by Sarah Vaughter,
a pioneer in lufenuron/candida treatment. It has quite a number of valuable insights, however, it also has comments that run counter to
our own experiences. (For example, Sarah pooh-poohs the use of natural vermifuges, which is just nonsense. We live near the Amazon, and
nasty parasites are so prevalent that nature vermifuges are integral to the health of entire tribes. They are central to their
ethnobotany.) Her comments marginalizing the importance of diet is also, in our opinion, not helpful, if not misleading.
Rebuttal to Comments from Dr. McCombs' Candida Plan Site -- This is a doctor who has his own Candida treatment plan.
I've done a cursory examination of it, have no critical comments to say about it. He has a three bottle program that
uses undecenoic acid as an anti-fungal agent, his own probiotic, and something he calls "Detox Essentials." He also coaches with
dietary and other lifestyle advise.

I don't know anyone who's used these products, so I can't say anything -- good or bad.

The reason I mention this link here is because this Dr. McCombs does a hatchet job on
lufenuron that not only doesn't comport with my associate's experience with lufenuron, having worked with many hundreds of people,
but flies in the face of the more credible material I've read in the extent literature. I'll go one step farther: if lufenuron was
capable of doing half the things Dr. McCombs says it does, I wouldn't even bother with it. This is, however, not the case.
The studies he does site appear extremely bias and remind me of the article I wrote last January (2020) about corruption in the medical
journal business. (See:
Official Medical "Science" in Retreat.